scholarly journals STUDY OF ACCUMULATION OF FLUPHENAZINE ENANTHATE AND FLUPHENAZINE DECANOATE, LONG-ACTING NEUROLEPTIC DRUGS, AFTER REPEATED ADMINISTRATIONS BY MEANS OF THEIR INHIBITORY EFFECTS ON THE DISCRIMINATED AVOIDANCE RESPONSE IN RATS

1979 ◽  
Vol 4 (2) ◽  
pp. 87-98 ◽  
Author(s):  
Hisashi KURIBARA ◽  
Sakutaro TADOKORO
Keyword(s):  
Avoidance Response ◽  
Neuroleptic Drugs ◽  
Inhibitory Effects ◽  
Fluphenazine Decanoate ◽  
Repeated Administrations ◽  
Fluphenazine Enanthate ◽  
Long Acting

Long-acting injectable antipsychotic agents

1979 ◽  
Vol 17 (11) ◽  
pp. 41-43
Keyword(s):  
Antipsychotic Agents ◽  
Fluphenazine Decanoate ◽  
Fluphenazine Enanthate ◽  
Long Acting ◽  
Flupenthixol Decanoate

Five long-acting injectable antipsychotic agents (neuroleptics) are available. They are fluphenazine enanthate (Moditen enanthate),1 fluphenazine decanoate (Modecate),2 flupenthixol decanoate (Depixol), cis-clopenthixol decanoate (Clopixol) and fluspirilene (Redeptin).3 Their therapeutic and unwanted effects are broadly similar to those of their oral forms. Nevertheless, injectable preparations have distinct advantages as well as problems.

The Side-Effects of Fluphenazine Decanoate

1973 ◽  
Vol 123 (576) ◽  
pp. 519-522 ◽  
Author(s):  
D. A. W. Johnson
Keyword(s):  
Side Effects ◽  
Clinical Situation ◽  
Fluphenazine Decanoate ◽  
Clinical Control ◽  
Hyper Sensitivity ◽  
Fluphenazine Enanthate ◽  
Extrapyramidal Effects ◽  
Low Incidence ◽  
Long Acting ◽  
Dose Dependent

The unwanted effects of the phenothiazines can be divided into two categories; those effects which represent the pharmacodynamic actions of a particular drug and occur as a function of dosage and individual susceptibility; and the hyper-sensitivity reactions (Shepherd et al., 1968). This latter group of side-effects is relatively rare, and there is no suggestion in the literature that they occur more frequently with the injectable long-acting phenothiazines (LAP) than with the oral forms. With the first available long-acting phenothiazine (fluphenazine enanthate) motor side-effects were frequently observed, particularly during the first few days after injection (Millar and Daniel, 1967; Lowther, 1969; Malm, 1970). Initial studies have suggested that fluphenazine decanoate is less likely to produce these unwanted extrapyramidal effects (Neal and Imlah, 1968; Ayd, 1970). So far, however, no study has attempted to make a quantitative evaluation of the problem of side-effects in the clinical situation of longterm medication. Since both the therapeutic efficacy and the unwanted extra-pyramidal side-effects are dose-dependent, it is meaningless to measure the incidence of side-effects without also recording the therapeutic gain: a low incidence of side-effects might only reflect a non-therapeutic dose of medication. Further, any such study should be continued for at least two months after the last reduction in dosage, as it is well recognized that loss of clinical control may be postponed for many weeks after phenothiazines have been discontinued.

Treatment of Severe Cryptosporidium-Related Diarrhea with Octreotide in a Patient with AIDS

1988 ◽  
Vol 22 (2) ◽  
pp. 134-136 ◽  
Author(s):  
Michael D. Katz ◽  
Brian L. Erstad ◽  
Cathryn Rose
Keyword(s):  
Gastrointestinal Hormones ◽  
Somatostatin Analog ◽  
Secretory Diarrhea ◽  
Inhibitory Effects ◽  
Severe Diarrhea ◽  
Immunosuppressed Patients ◽  
Acquired Immunodeficiency ◽  
Antiparasitic Drugs ◽  
Long Acting ◽  
Immunodeficiency Syndrome

Cryptosporidiosis commonly causes severe diarrhea in immunosuppressed patients. There currently are no antiparasitic drugs consistently effective for this infection. This case describes a 26-year-old hemophiliac patient with acquired immunodeficiency syndrome and cryptosporidiosis whose diarrhea improved with continuous intravenous administration of a long-acting somatostatin analog, octreotide. Somatostatin has a variety of inhibitory effects on gastrointestinal hormones as well as a possible nonspecific effect on gastrointestinal mucosal fluid and electrolyte secretion. The somatostatin analog should be considered for patients with secretory diarrhea refractory to other forms of therapy.

The Expectation of Outcome from Maintenance Therapy in Chronic Schizophrenic Patients

1976 ◽  
Vol 128 (3) ◽  
pp. 246-250 ◽  
Author(s):  
D. A. W. Johnson
Keyword(s):  
Maintenance Therapy ◽  
Patient Population ◽  
Significant Proportion ◽  
Community Services ◽  
Neuroleptic Drugs ◽  
Follow Up Study ◽  
High Incidence ◽  
Schizophrenic Patients ◽  
Long Acting

SummaryThe results from a prospective follow-up study of a group of schizophrenic patients suggest that a significant proportion (41 per cent) are likely to relapse during a two-year period despite the prescription of long-acting injectable neuroleptic drugs. Some will relapse because of a failure of the regime, but others (32–37 per cent) because the pharmacological protection of these drugs would appear to be less effective in certain patients. Even with the major advantages of the long-acting injectable neuroleptics over oral medication, the schizophrenic patient population remains a group with a high incidence of psychiatric and social morbidity which continues to require the full resources of both the hospital and community services.

A Controlled Trial of Fluphenazine Enanthate in Hospitalized Chronic Schizophrenics

1968 ◽  
Vol 114 (512) ◽  
pp. 837-841 ◽  
Author(s):  
Ijaz Haider
Keyword(s):  
Controlled Trial ◽  
Chronic Schizophrenics ◽  
Schizophrenic Patients ◽  
Fluphenazine Enanthate ◽  
Prescribed Medicines ◽  
Long Acting

The need for a long-acting phenothiazine has been long recognized, especially since it has been shown (Parkeset al., 1962; Rentonet al., 1963; Kline, 1964; Willcoxet al., 1965; Wilson and Enoch, 1967) that a high proportion of schizophrenic patients do not take their prescribed medicines.

Sign in / Sign up

Export Citation Format

Share Document